Companies
Seagen
Advanced therapeutics — Precision targeting.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $2.276 billion total funding raised prior to acquisition | pfizer.com |
| Production site | Bothell, Washington (existing manufacturing site); Everett, Washington (planned facility cancelled in 2024) | businesswire.com · fiercepharma.com · pharmaceutical-technology.com |
| Headcount | approximately 2,800 worldwide, with 1,600-1,800 in the Pacific Northwest as of 2022; reduced to 418 employees in LinkedIn profile by late 2023 | biopharmadive.com · businesswire.com · geekwire.com |
| Revenue | $2.0 billion for full year 2022 | firstwordpharma.com · pfizer.com · sec.gov |
| Regulatory approval | Received all required regulatory approvals for Pfizer acquisition in December 2023 | timesofindia.indiatimes.com · pfizer.com |
| Capacity | Planned 270,000-square-foot facility in Everett cancelled; production moved to Pfizer's Sanford, North Carolina site medium confidence | fiercepharma.com · pharmaceutical-technology.com |
Independent sources: biopharmadive.com · businesswire.com · fiercepharma.com · firstwordpharma.com · geekwire.com · pfizer.com · pharmaceutical-technology.com · sec.gov · timesofindia.indiatimes.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Antibody-drug conjugates (ADCs) | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.